<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Immunitybio Inc — News on 6ix</title>
    <link>https://6ix.com/company/immunitybio-inc</link>
    <description>Latest news and press releases for Immunitybio Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 11:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/immunitybio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835814778dffbe2df0fbc8e.webp</url>
      <title>Immunitybio Inc</title>
      <link>https://6ix.com/company/immunitybio-inc</link>
    </image>
    <item>
      <title>ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-announces-anktivar-is-now-available-in-saudi-arabia-for-bladder-and-lung-cancer-patients-market-entry-achieved-within-two-months-of-mena-partnership</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-announces-anktivar-is-now-available-in-saudi-arabia-for-bladder-and-lung-cancer-patients-market-entry-achieved-within-two-months-of-mena-partnership</guid>
      <pubDate>Tue, 21 Apr 2026 11:30:00 GMT</pubDate>
      <description>CULVER CITY, Calif., April 21, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia. Initial patients have been identified for treatment across both approved bladder and lung cancer indications in the Kingdom:</description>
    </item>
    <item>
      <title>ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-reports-net-product-revenue-increased-nearly-27-times-year-over-year-to-record-dollar44-million-in-q1-2026-and-dollar381-million-in-cash-and-marketable-securities</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-reports-net-product-revenue-increased-nearly-27-times-year-over-year-to-record-dollar44-million-in-q1-2026-and-dollar381-million-in-cash-and-marketable-securities</guid>
      <pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
      <description>Preliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 Consistent</description>
    </item>
    <item>
      <title>ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-addresses-fda-correspondence-and-reaffirms-commitment-to-advertising-compliance</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-addresses-fda-correspondence-and-reaffirms-commitment-to-advertising-compliance</guid>
      <pubDate>Mon, 06 Apr 2026 11:30:00 GMT</pubDate>
      <description>CULVER CITY, Calif., April 06, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it has submitted a comprehensive response to the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) regarding issues raised on March 13, 2026 related to a television advertisement and a podcast. The company addressed the concerns related to the podcast and informed OPDP that the television advertisement was never aired.</description>
    </item>
    <item>
      <title>ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-strengthens-balance-sheet-with-dollar100-million-of-financing-transactions-including-dollar75-million-of-non-dilutive-financing-to-support-global-expansion-and-advancement-of-broader-immunotherapy-pipeline</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-strengthens-balance-sheet-with-dollar100-million-of-financing-transactions-including-dollar75-million-of-non-dilutive-financing-to-support-global-expansion-and-advancement-of-broader-immunotherapy-pipeline</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>ImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total</description>
    </item>
    <item>
      <title>ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-confirms-statistical-power-in-pivotal-randomized-bcg-naive-nmibc-trial-to-detect-clinically-meaningful-differences-between-anktivar-plus-bcg-versus-bcg-alone-supplemental-bla-submission-on-track-for-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-confirms-statistical-power-in-pivotal-randomized-bcg-naive-nmibc-trial-to-detect-clinically-meaningful-differences-between-anktivar-plus-bcg-versus-bcg-alone-supplemental-bla-submission-on-track-for-2026</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>The QUILT-2.005 randomized clinical trial is on track for final analysis and supplemental Biologics License Application (BLA) submission in 2026 for the</description>
    </item>
    <item>
      <title>ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-announces-approval-in-macau-sar-china-for-anktivar-in-bcg-unresponsive-nmibc-with-cis-papillary-tumors</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-announces-approval-in-macau-sar-china-for-anktivar-in-bcg-unresponsive-nmibc-with-cis-papillary-tumors</guid>
      <pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
      <description>Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary</description>
    </item>
    <item>
      <title>ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-announces-nccnr-clinical-practice-guidelines-in-oncology-have-been-updated-to-include-anktivar-plus-bcg-for-patients-with-bcg-unresponsive-nmibc-with-papillary-only-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-announces-nccnr-clinical-practice-guidelines-in-oncology-have-been-updated-to-include-anktivar-plus-bcg-for-patients-with-bcg-unresponsive-nmibc-with-papillary-only-disease</guid>
      <pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
      <description>CULVER CITY, Calif., March 17, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease.</description>
    </item>
    <item>
      <title>ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-achieves-milestone-with-large-scale-nk-cell-production-and-cryopreservation-from-over-60-healthy-and-cancer-donors</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-achieves-milestone-with-large-scale-nk-cell-production-and-cryopreservation-from-over-60-healthy-and-cancer-donors</guid>
      <pubDate>Fri, 13 Mar 2026 11:30:00 GMT</pubDate>
      <description>CULVER CITY, Calif., March 13, 2026--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform.</description>
    </item>
    <item>
      <title>ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-announces-resubmission-of-supplemental-bla-to-the-fda-for-anktivar-plus-bcg-in-bcg-unresponsive-nmibc-with-papillary-disease-following-agency-review-of-additional-data</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-announces-resubmission-of-supplemental-bla-to-the-fda-for-anktivar-plus-bcg-in-bcg-unresponsive-nmibc-with-papillary-disease-following-agency-review-of-additional-data</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for</description>
    </item>
    <item>
      <title>ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-to-provide-a-business-update-and-review-financial-results-for-fy-2025-on-tuesday-march-3-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-to-provide-a-business-update-and-review-financial-results-for-fy-2025-on-tuesday-march-3-2026</guid>
      <pubDate>Fri, 27 Feb 2026 12:30:00 GMT</pubDate>
      <description>CULVER CITY, Calif., February 27, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company’s clinical trial pipeline, and to review financial results for the year ended December 31, 2025.</description>
    </item>
    <item>
      <title>ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-completes-enrollment-in-pivotal-randomized-trial-evaluating-anktivar-plus-bcg-versus-bcg-alone-in-bcg-naive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-completes-enrollment-in-pivotal-randomized-trial-evaluating-anktivar-plus-bcg-versus-bcg-alone-in-bcg-naive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ</guid>
      <pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
      <description>CULVER CITY, Calif., February 26, 2026--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary tumors.</description>
    </item>
    <item>
      <title>ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation &quot;Cancer 2035: A Roadmap for the Future&quot; Summit</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-founder-dr-patrick-soon-shiong-to-speak-at-milken-institute-and-richard-nixon-foundation-cancer-2035-a-roadmap-for-the-future-summit</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-founder-dr-patrick-soon-shiong-to-speak-at-milken-institute-and-richard-nixon-foundation-cancer-2035-a-roadmap-for-the-future-summit</guid>
      <pubDate>Mon, 23 Feb 2026 21:15:00 GMT</pubDate>
      <description>CULVER CITY, Calif., February 23, 2026--ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, will participate as a featured speaker at &quot;Cancer 2035: A Roadmap for the Future,&quot; a landmark summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C. on February 23–24, 2026.</description>
    </item>
    <item>
      <title>ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-reports-700percent-year-over-year-revenue-growth-expanded-anktivar-approvals-in-lung-cancer-and-global-commercial-partnerships-in-33-countries-with-label-expansion-plans-globally</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-reports-700percent-year-over-year-revenue-growth-expanded-anktivar-approvals-in-lung-cancer-and-global-commercial-partnerships-in-33-countries-with-label-expansion-plans-globally</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an</description>
    </item>
    <item>
      <title>ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-partners-with-biopharma-and-cigalah-healthcare-to-launch-anktivar-in-saudi-arabia-for-bladder-and-lung-cancer-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-partners-with-biopharma-and-cigalah-healthcare-to-launch-anktivar-in-saudi-arabia-for-bladder-and-lung-cancer-patients</guid>
      <pubDate>Fri, 20 Feb 2026 13:30:00 GMT</pubDate>
      <description>CULVER CITY, Calif., February 20, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA region.</description>
    </item>
    <item>
      <title>ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-expands-access-to-anktivar-in-eu-with-new-distribution-partnership-and-opens-irish-subsidiary-to-support-european-launch</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-expands-access-to-anktivar-in-eu-with-new-distribution-partnership-and-opens-irish-subsidiary-to-support-european-launch</guid>
      <pubDate>Thu, 19 Feb 2026 14:00:00 GMT</pubDate>
      <description>CULVER CITY, Calif., February 19, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for eligible patients in the European Union with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), with or without papillary disease. ImmunityBio also announced the establishment of an I</description>
    </item>
    <item>
      <title>ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-receives-authorization-from-the-european-commission-for-anktivar-with-bcg-for-non-muscle-invasive-bladder-cancer-carcinoma-in-situ-expanding-global-access-to-33-countries</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-receives-authorization-from-the-european-commission-for-anktivar-with-bcg-for-non-muscle-invasive-bladder-cancer-carcinoma-in-situ-expanding-global-access-to-33-countries</guid>
      <pubDate>Wed, 18 Feb 2026 14:00:00 GMT</pubDate>
      <description>CULVER CITY, Calif., February 18, 2026--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary tumors.</description>
    </item>
    <item>
      <title>ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-reports-productive-regulatory-engagement-with-saudi-food-and-drug-authority-at-usa-saudi-biotech-alliance-meeting-hosted-by-the-ministry-of-investment-of-saudi-arabia</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-reports-productive-regulatory-engagement-with-saudi-food-and-drug-authority-at-usa-saudi-biotech-alliance-meeting-hosted-by-the-ministry-of-investment-of-saudi-arabia</guid>
      <pubDate>Tue, 17 Feb 2026 11:07:00 GMT</pubDate>
      <description>CULVER CITY, Calif., February 17, 2026--ImmunityBio, Inc. (NYSE: IBRX), a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune competence, today announced that the Company held productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) in Riyadh, convened under the Saudi-USA Biotech Alliance hosted by the Ministry of Investment of Saudi Arabia (MISA). The engagement advanced two regulatory priorities:</description>
    </item>
    <item>
      <title>ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell-therapy-trial-anktivar</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell-therapy-trial-anktivar</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen to be evaluated in indolent</description>
    </item>
    <item>
      <title>ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-reports-median-overall-survival-not-yet-reached-and-lymphopenia-reversed</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-reports-median-overall-survival-not-yet-reached-and-lymphopenia-reversed</guid>
      <pubDate>Fri, 23 Jan 2026 05:00:00 GMT</pubDate>
      <description>Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of 23 enrolled patients alive as of January</description>
    </item>
    <item>
      <title>ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer</title>
      <link>https://6ix.com/company/immunitybio-inc/news/immunitybio-advances-regulatory-discussions-fda-potential-resubmission-path-anktivar</link>
      <guid isPermaLink="true">https://6ix.com/company/immunitybio-inc/news/immunitybio-advances-regulatory-discussions-fda-potential-resubmission-path-anktivar</guid>
      <pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
      <description>Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to</description>
    </item>
  </channel>
</rss>